Current Problems in the Management of Chronic Myeloid Leukemia in Turkey


DEMİRKAN F.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, vol.21, no.2, pp.24-28, 2011 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Review
  • Volume: 21 Issue: 2
  • Publication Date: 2011
  • Doi Number: 10.4999/uhod.11015
  • Journal Name: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.24-28
  • Keywords: Chronic myeloid leukemia, Tyrosine kinase inhibitors, BCR/ABL, CHRONIC MYELOGENOUS LEUKEMIA, PATIENTS RECEIVING IMATINIB, CHRONIC-PHASE, MOLECULAR RESPONSES, FOLLOW-UP, INTERFERON, DASATINIB, THERAPY
  • Dokuz Eylül University Affiliated: Yes

Abstract

Although a large scale survey investigating the practice patterns of physicians for Chronic Myeloid Leukemia (CML) throughout Turkey is absent, there is an increasing enthusiasm on this subject after several years of experience with Tyrosine Kinase Inhibitors (TKI) therapy. Considering the problems in the management of CML patients, we can focus on deficiencies in the laboratory tests for diagnosis and monitoring, management of suboptimal response with imatinib therapy and conducting visit frequency of patients.